

Supplemental Information for

Novel genetically-humanized mouse model established to evaluate efficacy of therapeutic agents to human interleukin-6 receptor

Otoya Ueda¹, Hiromi Tateishi², Yoshinobu Higuchi¹, Etsuko Fujii¹, Atsuhiko Kato¹, Yosuke Kawase², Naoko A. Wada^{1,2}, Takanori Tachibe², Mami Kakefuda², Chisato Goto², Makoto Kawaharada², Shin Shimaoka¹, Kunihiro Hattori¹ and Kou-ichi Jishage^{1*}

¹Chugai Pharmaceutical Co. Ltd., Fuji-Gotemba Research Laboratories, 1-135, Komakado, Gotemba, Shizuoka, Japan.

² Chugai Research Institute for Medical Science Inc. 1-135, Komakado, Gotemba, Shizuoka, Japan.


*To whom correspondence should be addressed:

jishagekui@chugai-pharm.co.jp

Supplementary information includes

Supplementary Figure S1

Supplementary Figure S1: Marked and specific prevention of splenomegaly in humanized Castleman's disease mouse model with the treatment of hIL6R-specific neutralizing antibody.



Supplementary Figure S1. Both *Il6ra*^{hIL6R/hIL6R}-*hIL6* transgenic mice and *Il6ra*^{+/+}-*hIL6* transgenic mice were treated with physiological saline, the anti-mouse *Il6ra* antibody, MR16-1, or the anti-human *IL6R* antibody, tocilizumab (TCZ). Number at the bottom of each spleen denotes the animal ID number. Marked and specific prevention of splenomegaly was observed in *Il6ra*^{hIL6R/hIL6R}-*hIL6* transgenic mice (animal ID#174, 176, 187, 264 and 274) with the treatment of TCZ, but not with MR16-1 (#360, 362, 192, 193 and 261). In contrast, in *Il6ra*^{+/+}-*hIL6* transgenic mice TCZ treatment does not

show preventive effects on the splenomegaly (#133, 180, 277, 287 and 377), whereas

MR16-1 markedly prevented splenomegaly (#69, 189, 366, 384 and 396).